Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-LAG-3 Monoclonal Antibody BMS-986016

Known as: BMS-986016, BMS986016 
A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and… Expand
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The tumour microenvironment (TME) in PDA is… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2019
2019
Abstract B076: Pan-cancer analysis to identify which cancers may benefit most from LAG-3 blockade
Immune checkpoint blockade using antibodies that target programmed-cell-death-1 (PD-1) or its ligand programmed-cell-death-ligand… Expand
Is this relevant?
2018
2018
Lag-3 Mediates Acute Rejection & Memory In Mouse Transplantation
Lymphocyte Activation Gene-3 (LAG-3) is a soluble protein and transmembrane protein receptor expressed on lymphocytes such as… Expand
  • figure 2
  • table 1
  • figure 4
  • figure 6
  • figure 7
Is this relevant?
2017
2017
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
9520Background: Signaling via LAG-3 and other T-cell inhibitory receptors (eg, PD-1) can lead to T-cell dysfunction and tumor… Expand
Is this relevant?
2017
2017
LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1…
 
Is this relevant?
Review
2017
Review
2017
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas
Tumor cells can evade immune surveillance through overexpressing the ligands of checkpoint receptors on tumor cells or adjacent… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Immunotherapies targeting the programmed death 1 (PD-1) coinhibitory receptor have shown great promise for a subset of patients… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE